NCT07453862 is a Phase 1 clinical trial of Crisugabalin in Restless Leg Syndrome (RLS), sponsored by Beijing Friendship Hospital.

Who is sponsoring NCT07453862?

NCT07453862 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT07453862?

Interventions in NCT07453862: Crisugabalin.

What condition does NCT07453862 study?

NCT07453862 studies Restless Leg Syndrome (RLS), Variant Restless Legs Syndrome.

Is NCT07453862 still recruiting?

NCT07453862 is currently recruiting now. Last updated 6 March 2026.

Last reviewed 2026-03-06 · How we verify

NCT07453862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety

Recruiting now Phase 1 Last updated 6 March 2026

What this trial tests

Phase 1 trial testing Crisugabalin in Restless Leg Syndrome (RLS) in 20 participants. Currently enrolling.

Timeline

10 March 2026

Primary endpoint
30 June 2027

31 August 2027

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	10 March 2026
Primary completion	30 June 2027
Estimated completion	31 August 2027
Sites	1 location across China

Drugs / interventions tested

Crisugabalin — full drug profile →

Conditions studied

Restless Leg Syndrome (RLS) — all drugs for Restless Leg Syndrome (RLS) →
Variant Restless Legs Syndrome — all drugs for Variant Restless Legs Syndrome →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 18 to 75, any sex, with Restless Leg Syndrome (RLS) or Variant Restless Legs Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this \[study type: clinical trial\] is to \[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\] in \[describe participant population/primary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\]. The main question\[s\] it aims to answer \[is/are\]: * Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period? * What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients? Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given\]: * Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks * Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Crisugabalin

Trials testing the same drug.

NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
NCT07196657 — The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia · NA · recruiting
NCT06766916 — Crisugabalin for Radiotherapy-Related Neuropathic Pain · Phase 2 · recruiting

Other recruiting trials for Restless Leg Syndrome (RLS)

Currently open trials in the same condition.

NCT07144631 — Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome · NA · recruiting
NCT07179406 — The Effect of Spinal Cord Stimulators on Restless Leg Syndrome · NA · recruiting
NCT06726785 — Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist · recruiting
NCT06747741 — Effects of PNF Stretching vs Conventional Physical Therapy on the Symptoms of Restless Leg Syndrome in Elderly Populatio · NA · recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
NCT07332104 — The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Ga · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07453862 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 6 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07453862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing